Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA

BACKGROUND: Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour DNA (ctDNA). Low-pass whole-genome sequencing (lpWGS) of ctDNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumanasuriya, Semini, Seed, George, Parr, Harry, Christova, Rossitza, Pope, Lorna, Bertan, Claudia, Bianchini, Diletta, Rescigno, Pasquale, Figueiredo, Ines, Goodall, Jane, Fowler, Gemma, Flohr, Penelope, Mehra, Niven, Neeb, Antje, Rekowski, Jan, Eisenberger, Mario, Sartor, Oliver, Oudard, Stéphane, Geffriaud-Ricouard, Christine, Ozatilgan, Ayse, Chadjaa, Mustapha, Macé, Sandrine, Lord, Chris, Baxter, Joe, Pettitt, Stephen, Lambros, Maryou, Sharp, Adam, Mateo, Joaquin, Carreira, Suzanne, Yuan, Wei, de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329366/
https://www.ncbi.nlm.nih.gov/pubmed/34103179
http://dx.doi.org/10.1016/j.eururo.2021.05.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329366/
https://www.ncbi.nlm.nih.gov/pubmed/34103179
http://dx.doi.org/10.1016/j.eururo.2021.05.030

Ejemplares similares